JADE BIOSCIENCES INC (JBIO) Stock Price, Forecast & Analysis
NASDAQ:JBIO • US0080642061
JBIO Key Statistics, Chart & Performance
The current stock price of JBIO is 14.27 USD. In the past month the price decreased by -16.16%.
JBIO Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to JBIO.
JBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to JBIO. While JBIO has a great health rating, there are worries on its profitability.
JBIO Financial Highlights
Over the last trailing twelve months JBIO reported a non-GAAP Earnings per Share(EPS) of -11.14. The EPS increased by 89.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.23% | ||
| ROE | -36.39% | ||
| Debt/Equity | 0 |
JBIO Forecast & Estimates
14 analysts have analysed JBIO and the average price target is 22.44 USD. This implies a price increase of 57.25% is expected in the next year compared to the current price of 14.27.
JBIO Ownership
JBIO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.48 | 396.512B | ||
| AMGN | AMGEN INC | 16.63 | 202.199B | ||
| GILD | GILEAD SCIENCES INC | 16.97 | 187.492B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.39 | 119.063B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.78 | 82.713B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.19 | 44.834B | ||
| INSM | INSMED INC | N/A | 34.336B | ||
| NTRA | NATERA INC | N/A | 30.104B | ||
| BIIB | BIOGEN INC | 12.62 | 28.19B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.691B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About JBIO
Company Profile
Jade Biosciences, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. The company is headquartered in Waltham, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2021-06-30. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
Company Info
JADE BIOSCIENCES INC
221 Crescent St., Building 23, Suite 105
Waltham MASSACHUSETTS US
Employees: 4
Phone: 17813123013
JADE BIOSCIENCES INC / JBIO FAQ
What does JBIO do?
Jade Biosciences, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. The company is headquartered in Waltham, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2021-06-30. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
What is the current price of JBIO stock?
The current stock price of JBIO is 14.27 USD. The price decreased by -1.92% in the last trading session.
What is the dividend status of JADE BIOSCIENCES INC?
JADE BIOSCIENCES INC (JBIO) has a dividend yield of 558.88%. The yearly dividend amount is currently 0.
How is the ChartMill rating for JADE BIOSCIENCES INC?
JBIO has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the number of employees for JADE BIOSCIENCES INC?
JADE BIOSCIENCES INC (JBIO) currently has 4 employees.
What is the market capitalization of JBIO stock?
JADE BIOSCIENCES INC (JBIO) has a market capitalization of 703.65M USD. This makes JBIO a Small Cap stock.
Can you provide the short interest for JBIO stock?
The outstanding short interest for JADE BIOSCIENCES INC (JBIO) is 3.09% of its float.